Browse > Article

Restoration of Blood Pressure after Administering Methylene Blue for Vasoplegic Syndrome, which Developed after Open Heart Surgery for Septic Infective Endocarditis -A case report -  

Lee, Sak (Department of Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine)
Bae, Mi-Kyung (Department of Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine)
Yi, Gi-Jong (Department of Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine)
Youn, Young-Nam (Department of Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine)
Song, Suk-Won (Department of Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine)
Kim, Do-Kyun (Department of Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine)
Publication Information
Journal of Chest Surgery / v.40, no.4, 2007 , pp. 305-308 More about this Journal
Abstract
Vasoplegic syndrome occurs in $8{\sim}10%$ of patients following cardiac surgery, and this happens in part because of inducing the inflammatory response. Nitric oxide and guanylate cyclase play an important role in this response, and this is associated with increased morbidity and mortality. For our case, we administered methylene blue (MB), an inhibitor of guanylate cyclase, early after performing cardiopulmonary bypass in a patient with vasoplegic syndrome. The patient recovered immediately after MB administration and maintained an optimal blood pressure without the aid help of any vasopressors.
Keywords
Cardiopulmonary bypass; Methylene blue; Vasoplegic syndrome;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Leyh RG, Kofidis T, Struber M, et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2003;125:1426-31   DOI   ScienceOn
2 Evora PR, Ribeiro PJ, De Andrade JC. Methylene blue administration in SIRS after cardiac operations. Ann Thorac Surg 1997;63:1212-3   DOI   PUBMED   ScienceOn
3 Mekontso-Dessap A, Houel R, Soustelle C, Kirsch M, Thebert D, Loisance DY. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 2001;71:1428-32   DOI   ScienceOn
4 Shanmugam G. Vasoplegic syndrome - the role of Methylene blue. Eur J Cardiothorac Surg 2005;28:705-10   DOI   ScienceOn
5 Grayling M, Deakin CD. Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis. J Thorac Cardiovasc Surg 2003;125:426-7   DOI   ScienceOn
6 Maslow AD, Stearns G, Batula P, Schwartz CS, Gough J, Singh AK. The hemodynamic effects of Methylene blue when administered at the onset of cardiopulmonary bypass. Anesth Analg 2006;103:2-8   DOI   ScienceOn
7 Taylor K. SIRS: the systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996;61:1607-8   DOI   PUBMED   ScienceOn
8 Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004;77:496-9   DOI   ScienceOn